These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22706853)

  • 61. Metabolomic Laboratory-Developed Tests: Current Status and Perspectives.
    Lichtenberg S; Trifonova OP; Maslov DL; Balashova EE; Lokhov PG
    Metabolites; 2021 Jun; 11(7):. PubMed ID: 34206934
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CLIA-88 final rule: Part 1.
    Voldish K
    N J Med; 1992 Aug; 89(8):601-4. PubMed ID: 1513507
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantitative tandem mass spectrometry in the clinical laboratory: Regulation and opportunity for validation of laboratory developed tests.
    Stone JA; van der Gugten JG
    J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():82-90. PubMed ID: 36937811
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quality assurance in nuclear medicine facilities; availability of final recommendations--FDA. Notice.
    Fed Regist; 1985 May; 50(92):20011-2. PubMed ID: 10271280
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pre-analytical errors: working with manufacturers to help improve quality.
    Daugherty K
    MLO Med Lab Obs; 2014 Feb; 46(2):18, 20. PubMed ID: 24672848
    [No Abstract]   [Full Text] [Related]  

  • 66. Q&A on QA.
    Lepore PD
    Toxicol Pathol; 1996; 24(5):657-8. PubMed ID: 9053964
    [No Abstract]   [Full Text] [Related]  

  • 67. A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests.
    Graden KC; Bennett SA; Delaney SR; Gill HE; Willrich MAV
    Lab Med; 2021 Jul; 52(4):315-328. PubMed ID: 33283241
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The human costs of over-regulation.
    Murray DC
    Pacing Clin Electrophysiol; 1996 Mar; 19(3):360-2. PubMed ID: 8657598
    [No Abstract]   [Full Text] [Related]  

  • 69. Clinical chemistry devices; classification of the biotinidase test system. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Mar; 65(61):16520-1. PubMed ID: 11010644
    [TBL] [Abstract][Full Text] [Related]  

  • 70. LDTs and the FDA: The saga continues.
    Longwell A
    MLO Med Lab Obs; 2017 Apr; 49(4):40, 43. PubMed ID: 29979012
    [No Abstract]   [Full Text] [Related]  

  • 71. Obstacles remain on road to digital mammography.
    Johnson M
    Diagn Imaging (San Franc); 1999 Nov; Suppl Digital():D19-21. PubMed ID: 10724731
    [No Abstract]   [Full Text] [Related]  

  • 72. Impact of VALID Act implementation on mass spectrometry-based clinical proteomic laboratory developed tests.
    Lin Y; Thomas SN
    J Mass Spectrom Adv Clin Lab; 2023 Apr; 28():30-34. PubMed ID: 36865788
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The key to product quality assurance.
    Schwemer WL
    Food Drug Law J; 1998; 53(4):627-32. PubMed ID: 10557580
    [No Abstract]   [Full Text] [Related]  

  • 74. Laboratory developed tests: what may be coming.
    Jones PM
    MLO Med Lab Obs; 2012 Oct; 44(10):24, 26. PubMed ID: 23091959
    [No Abstract]   [Full Text] [Related]  

  • 75. Tracing our roots: new opportunities and new challenges in clinical laboratory science (1977-1992).
    Kotlarz VR
    Clin Lab Sci; 2001; 14(1):13-8. PubMed ID: 15633489
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Approval of an alternative requirement of the Mammography Quality Standards Act; availability--FDA. Notice.
    Fed Regist; 1998 Nov; 63(216 Pt 1):60352. PubMed ID: 10187394
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of regulatory science on global public health.
    Patel M; Miller MA
    Kaohsiung J Med Sci; 2012 Jul; 28(7 Suppl):S5-9. PubMed ID: 22871603
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Medical devices; exemption from premarket notification and reserved devices; Class I--FDA. Proposed rule.
    Fed Regist; 1998 Nov; 63(218):63222-53. PubMed ID: 10187398
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Revolution of the health care delivery system and its impacts on laboratory testing in the United States].
    Takemura Y; Ishibashi M
    Rinsho Byori; 2000 Feb; 48(2):89-98. PubMed ID: 10804811
    [TBL] [Abstract][Full Text] [Related]  

  • 80. US Food and Drug Administration regulatory oversight of laboratory-developed tests: Commentary on the draft guidance.
    Sidawy MK
    Cancer Cytopathol; 2015 Oct; 123(10):573-5. PubMed ID: 26042383
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.